Hartman, A. Rift Valley Fever. Clin. Lab Med. 37, 285–301 (2017).
Bird, B. H., Ksiazek, T. G., Nichol, S. T. & Maclachlan, N. J. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 234, 883–893 (2009).
Gerken, K. N. et al. Paving the way for human vaccination against Rift Valley fever virus: A systematic literature review of RVFV epidemiology from 1999 to 2021. PLoS Negl. Trop. Dis. 16, e0009852 (2022).
Gerken, K. N. et al. Urban risk factors for human Rift Valley fever virus exposure in Kenya. PLoS Glob. Public Health 2, e0000505 (2022).
de Glanville, W. A. et al. An outbreak of Rift Valley fever among peri-urban dairy cattle in northern Tanzania. Trans. R. Soc. Trop. Med Hyg. 116, 1082–1090 (2022).
Pédarrieu, A., Piro-Megy, C., Quellec, J. & Cêtre-Sossah, C. Pasteurization temperatures effectively inactivate Rift Valley fever viruses in milk. J Virol, e0202624, https://doi.org/10.1128/jvi.02026-24 (2025).
Laughlin, L. W., Meegan, J. M., Strausbaugh, L. J., Morens, D. M. & Watten, R. H. Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. Trans. R. Soc. Trop. Med Hyg. 73, 630–633 (1979).
Coetzer, J. A. The pathology of Rift Valley fever. I. Lesions occurring in natural cases in new-born lambs. Onderstepoort J. Vet. Res. 44, 205–211 (1977).
Coetzer, J. A. The pathology of Rift Valley fever. II. Lesions occurring in field cases in adult cattle, calves and aborted foetuses. Onderstepoort J. Vet. Res. 49, 11–17 (1982).
McMillen, C. M. & Hartman, A. L. Rift Valley fever in animals and humans: Current perspectives. Antivir. Res. 156, 29–37 (2018).
Chengula, A. A., Mdegela, R. H. & Kasanga, C. J. Socio-economic impact of Rift Valley fever to pastoralists and agro pastoralists in Arusha, Manyara and Morogoro regions in Tanzania. Springerplus 2, 549 (2013).
Kim, Y. et al. The role of livestock movements in the spread of Rift Valley fever virus in animals and humans in Mayotte, 2018-19. PLoS Negl. Trop. Dis. 15, e0009202 (2021).
Ahmad, K. More deaths from Rift Valley fever in Saudi Arabia and Yemen. Lancet 356, 1422 (2000).
Hassan, O. A., Ahlm, C. & Evander, M. A need for One Health approach – lessons learned from outbreaks of Rift Valley fever in Saudi Arabia and Sudan. Infect Ecol. Epidemiol. 4, https://doi.org/10.3402/iee.v4.20710 (2014).
Alkan, C., Jurado-Cobena, E. & Ikegami, T. Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates. NPJ Vaccines 8, 171 (2023).
Métras, R. et al. Estimation of Rift Valley fever virus spillover to humans during the Mayotte 2018-2019 epidemic. Proc. Natl. Acad. Sci. USA 117, 24567–24574 (2020).
Botros, B. et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. J. Med Virol. 78, 787–791 (2006).
Makoschey, B. et al. Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths. PLoS Negl. Trop. Dis. 10, e0004550 (2016).
Hunter, P., Erasmus, B. J. & Vorster, J. H. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J. Vet. Res. 69, 95–98 (2002).
Bird, B. H. et al. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J. Virol. 82, 2681–2691 (2008).
Bird, B. H. et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J. Virol. 85, 12901–12909 (2011).
Smith, D. R. et al. Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. PLoS Negl. Trop. Dis. 12, e0006474 (2018).
Coalition for Epidemic Preparedness Innovations. CEPI partners with University of California, Davis to advance a vaccine against potentially deadly Rift Valley fever virus into clinical trials, https://cepi.net/cepi-partners-university-california-davis-advance-vaccine-against-potentially-deadly-rift-valley (2023).
Pravieux, J. J., Poulet, H., Charreyre, C. & Juillard, V. Protection of newborn animals through maternal immunization. J. Comp. Pathol. 137(Suppl 1), S32–34 (2007).
Pentsuk, N. & van der Laan, J. W. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res. B Dev. Reprod. Toxicol. 86, 328–344 (2009).
Barrington, G. M. & Parish, S. M. Bovine Neonatal Immunology. Vet. Clin. North Am.: Food Anim. Pract. 17, 463–476 (2001).
McMillen, C. M. et al. Rift Valley fever virus induces fetal demise in Sprague-Dawley rats through direct placental infection. Sci. Adv. 4, eaau9812 (2018).
Rusnak, J. M., Gibbs, P., Boudreau, E., Clizbe, D. P. & Pittman, P. Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study. Vaccine 29, 3222–3229 (2011).
Peyre, M. et al. A Systematic Scoping Study of the Socio-Economic Impact of Rift Valley Fever: Research Gaps and Needs. Zoonoses Public Health 62, 309–325 (2015).
Morrill, J. C. et al. Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves. Vaccine 31, 4988–4994 (2013).
Morrill, J. C. et al. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine 31, 559–565 (2013).
Boumart, Z. et al. Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12ΔNSm21/384 vaccine candidate for sheep, goats and calves. Vaccine 37, 1642–1650 (2019).
Boumart, Z. et al. Safety and immunogenicity of the Rift Valley fever arMP-12 ΔNSm21/384 candidate vaccine in pregnant ewes. Vaccine: X 6, 100070 (2020).
Ikegami, T. et al. Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models. NPJ Vaccines 7, 109 (2022).
Leroux-Roels, I. et al. Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial. Lancet Infect. Dis. 24, 1245–1253 (2024).
Jenkin, D. et al. Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial. Lancet Infect. Dis. 23, 956–964 (2023).
Wichgers Schreur, P. J., van Keulen, L., Kant, J. & Kortekaas, J. Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy. Vaccine 35, 3123–3128 (2017).
Wichgers Schreur, P. J. et al. A single vaccination with four-segmented Rift Valley fever virus prevents vertical transmission of the wild-type virus in pregnant ewes. npj Vaccines 6, 8 (2021).
Stedman, A. et al. Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats. NPJ Vaccines 4, 44 (2019).
U.S. Food & Drug Administration. FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants, https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants (2023).
Hasselquist, D. & Nilsson, J. A. Maternal transfer of antibodies in vertebrates: trans-generational effects on offspring immunity. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364, 51–60 (2009).
Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A. & Carneiro-Sampaio, M. IgG placental transfer in healthy and pathological pregnancies. Clin. Dev. Immunol. 2012, 985646 (2012).
Appleby, P. & Catty, D. Transmission of immunoglobulin to foetal and neonatal mice. J. Reprod. Immunol. 5, 203–213 (1983).
Fernandez, J.-C. et al. The Nonstructural Protein NSs Induces a Variable Antibody Response in Domestic Ruminants Naturally Infected with Rift Valley Fever Virus. Clin. Vaccin. Immunol. 19, 5–10 (2012).
Ikegami, T. & Makino, S. The pathogenesis of Rift Valley fever. Viruses 3, 493–519 (2011).
Harrington, D. G. et al. Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep. Am. J. Vet. Res 41, 1559–1564 (1980).
Watts, D. M. et al. Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. Am. J. Trop. Med Hyg. 107, 1091–1098 (2022).
Englund, J. A. et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 96, 580–584 (1995).
Knuutila, A. et al. Effect of immunization during pregnancy and pre-existing immunity on diphtheria-tetanus-acellular pertussis vaccine responses in infants. Emerg. Microbes Infect. 12, 2204146 (2023).
England, R. N. et al. Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model. npj Vaccines 9, 110 (2024).
McMillen, C. M. et al. Congenital Rift Valley fever in Sprague Dawley rats is associated with diffuse infection and pathology of the placenta. PLoS Negl. Trop. Dis. 16, e0010898 (2022).
McMillen, C. M. et al. A highly potent human neutralizing antibody prevents vertical transmission of Rift Valley fever virus in a rat model. Nat. Commun. 14, 4507 (2023).
McElroy, A. K., Albariño, C. G. & Nichol, S. T. Development of a RVFV ELISA that can distinguish infected from vaccinated animals. Virol. J. 6, 125 (2009).
Xu, L. et al. A Cross-Sectional Study of SARS-CoV-2 Seroprevalence between Fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA. Pathogens 10, https://doi.org/10.3390/pathogens10060710 (2021).
Harmon, J. R., Barbeau, D. J., Nichol, S. T., Spiropoulou, C. F. & McElroy, A. K. Rift Valley fever virus vaccination induces long-lived, antigen-specific human T cell responses. npj Vaccines 5, 17 (2020).
